Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Crenolanib + Cytarabine + Mitoxantrone |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Crenolanib | CP-868596|CP-868,596 | FLT3 Inhibitor 69 PDGFR Inhibitor (Pan) 30 | Crenolanib (CP-868596) is a type III receptor tyrosine kinase inhibitor of PDGFR-alpha/beta and FLT3, which results in inhibition of downstream signaling and prevents growth in tumor cells (PMID: 22745105, PMID: 24227820, PMID: 29137311, PMID: 31309543). | |
| Cytarabine | Cytosar-U | Ara-C | Cytosar-U (cytarabine) is a cytidine analog that, when incorporated into DNA, inhibits DNA synthesis and repair (PMID: 32524309). | |
| Mitoxantrone | Novantrone | CL 232315 | TOPO2 inhibitor 5 | Novantrone (mitoxantrone) binds to and inhibits topoisomerase II, leading to DNA double strand breaks and decreased DNA repair (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02626338 | Phase Ib/II | Crenolanib + Cytarabine + Mitoxantrone | Pilot Study of Crenolanib Combined With Cytarabine and Mitoxantrone in Subjects With R/R AML | Completed | USA | 0 |